

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O2 – Enrollment Summary by Site

Site	First Enrollment Date	Last Enrollment Date	Duration of Accrual (weeks)	Total Participants Enrolled	Number of Participants Replaced	Total Evaluable Participants	Average Evaluable and Enrolled per Week
Cleveland Clinic Main	19MAY2022	24SEP2024	122.0	5	0	5	0.0
Henry Ford	09MAY2023	10JAN2024	35.0	7	0	7	0.2
Intermountain	08MAR2022	24SEP2024	133.0	22	2	20	0.2
Johns Hopkins Bayview	12SEP2021	17JUL2024	148.0	33	0	33	0.2
Johns Hopkins Hosp.	17OCT2021	18SEP2024	152.0	32	2	30	0.2
Medical U South Carolina	14MAR2023	19SEP2024	79.0	7	0	7	0.1
Montefiore Moses	03FEB2022	23APR2024	115.0	6	1	5	0.0
Montefiore Weiler	08MAR2024	08MAR2024	0.0	1	0	1	.
Ohio State U	19APR2022	13SEP2024	125.0	13	0	13	0.1
U of Cincinnati	24AUG2021	03SEP2024	158.0	25	0	25	0.2
U of Colorado Denver	11NOV2021	09AUG2024	143.0	20	1	19	0.1
U of Michigan	16MAR2023	16MAR2023	0.0	1	0	1	.
U of Pittsburgh	04MAR2022	04MAR2022	0.0	1	0	1	.
U of Vermont	19NOV2021	29SEP2022	44.0	2	0	2	0.0
U of Wash. Harborview	29JUN2021	01MAR2024	139.0	9	0	9	0.1
U of Washington	26OCT2021	13DEC2023	111.0	4	0	4	0.0
Vanderbilt U	03NOV2022	22JUL2024	89.0	8	1	7	0.1
Wake Forest	11APR2022	07JUN2024	112.0	8	0	8	0.1
Washington U St Louis	01MAR2022	27SEP2024	134.0	9	1	8	0.1
All Sites	29JUN2021	27SEP2024	169.0	213	8	205	1.2